Navigation Links
Hovione Opens its New API Plant in Cork
Date:4/22/2009

CORK, Ireland, April 22 /PRNewswire/ -- Hovione held today the opening ceremony of its new active pharmaceutical ingredient manufacturing site in Cork. Hovione contracted with Pfizer last December to take over the site that had been manufacturing Lipitor(R) since 1997. The handover of the plant took place on April 6th and the transaction closed on the 8th; going forward Hovione will continue to perform a small amount of manufacture for Pfizer but will mostly make use of the available capacity to address its own production needs.

Hovione is a specialist developer and manufacturer and the Cork site will be used to produce active pharmaceutical ingredients (APIs) for a large range of pharmaceutical companies both large and small worldwide. Many customers find it more cost effective and less risky to manufacture APIs externally by a specialist, and see a contractor as a more flexible option that transforms fixed into variable costs, reduces risk, provides added value and assured results. By being the manufacturing partner to a large number of Innovators, Hovione is able to make sure its capacity is more readily occupied than if it was limited to producing in-house products, and is also thereby able to reduce production costs and the investment risk of equipping itself with the latest technologies.

Hovione's research centres -in New Jersey, USA and Lisbon, Portugal- assure the development and manufacture of clinical trial materials for a growing number of compounds, exceeding 40 last year alone. As these products progressed through clinical development, and some got ready for filing, Hovione felt it needed additional capacity to ensure it could continue to guaranty absolute assurance of supply to its customers. The Cork site addresses perfectly this need as it provides state-of-the-art manufacturing capacity and experienced staff precisely at the right moment.

"This site has been the API engine behind Lipitor(R), the most successful medicine ever. It is with this heritage that it joins the Hovione group and embraces the opportunities that come with a new business model. We will be transferring to the Cork site a number of compounds over the next 18 months - some were recently approved, others are growing fast and customers are looking for second sources, and finally Hovione's rich pipe-line of Phase III compounds need to have registration batches done at their commercial site of manufacture" - said Lorcan MacGarry, Hovione Cork's General Manager.

Over the last two years Hovione acquired two new, virtually empty, plants -Cork in Ireland, and Taizhou in China-. The latter is dedicated to serving generics with a high volume low cost strategy value proposition; the former is the ideal plant for a new product introduction for an Innovator that does not possess in-house API production. In this period Hovione has doubled manufacturing capacity to more than 1000m3 and now employs over 900 staff. Over the last 3 years Hovione sales have grown at 14% average per annum.

"The combination of the Cork Site's team and capabilities, with the custom synthesis business model is an unbeatable value proposition. This allows the pharma innovator company to have the best of both worlds - access to excellent facilities with best service and high levels of compliance without fixed costs and with capacity available on demand - and all this at the right address" said Guy Villax, Chief Executive.

About Hovione. Hovione is an international company with 50 years' experience in Active Pharmaceutical Ingredient development and compliant manufacture. With four FDA inspected sites in the US, China, Ireland and Portugal the company focuses on the most demanding customers, in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione, please visit the Hovione site at http://www.hovione.com or contact Corporate Communications, Isabel Pina, +351-91-7507-462 or +351-21-982-9362, e-mail: ipina@hovione.com.


'/>"/>
SOURCE Hovione
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hoviones TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza
2. Hovione Buys Pfizers Loughbeg API Facility
3. Hoviones Sales Grow 11%
4. Hovione Launches New Website
5. Hovione Buys Drug Manufacturing Facility in China
6. Alpine Biomed Opens New Manufacturing Facility to Support Demand for Specialty Diagnostic Devices
7. Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
8. Cells Exhibition Opens at Maryland Science Center
9. Gore PharmBIO Products Opens New Facility with State-of-the-Art-Cleanroom Facility Built to Support Demand for Growing STA-PURE(TM) Product Line
10. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
11. DNA 11, Creators of DNA Art, Opens First Pop-up Gallery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 2017 , ... LabRoots , the leading provider of scientific trending news ... is announcing a new textbook scholarship, the second scholarship in the LabRoots program. ... or older, pursuing a degree in one of the life sciences. The scholarship will ...
(Date:5/24/2017)... ... May 23, 2017 , ... ... provider of high quality relocatable and permanent modular buildings, announced the launch ... tools and modern office design characteristics to help support on-site teamwork and ...
(Date:5/24/2017)... Ebola resurfaces in the Democratic Republic of Congo ... reported, a new analysis of the Ebola gene polymerase Replikin ... 2014 and 2017 outbreaks of the disease.  ... the 2014 outbreak. An analysis of the latest data showed ... which again precedes the current outbreak in the DRC. Sequence ...
(Date:5/23/2017)... Yorba Linda, Ca (PRWEB) , ... ... ... stem cells (PSCs) offer an unlimited source of human cardiovascular cells for ... efficient cardiac-directed differentiation methods makes it possible to generate large numbers of ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
Breaking Biology News(10 mins):